FRANKLIN, Tenn. / Mar 02, 2023 / Business Wire / Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in two investor conferences in March.
On Tuesday, March 7, 2023, the Company will participate in the Raymond James 44th Annual Institutional Investors Conference, which is being held March 5 - 8, 2023, in Orlando, Florida. The Company’s presentation will be at 6:30 a.m. Central Time/7:30 a.m. Eastern Time.
On Wednesday, March 8, 2023, the Company will participate in the Cowen 43rd Annual Health Care Conference, to be held March 6 - 8, 2023, in Boston, Massachusetts. The Company’s presentation will be at 9:30 a.m. Central Time/10:30 a.m. Eastern Time.
The live webcast of both presentations will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investors” link. A replay of the presentation will also be available on the Company’s website for 30 days.
About Acadia
Acadia is a leading provider of behavioral healthcare services across the United States. As of December 31, 2022, Acadia operated a network of 250 behavioral healthcare facilities with approximately 11,000 beds in 39 states and Puerto Rico. With approximately 23,000 employees serving more than 75,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
Last Trade: | US$24.53 |
Daily Change: | 0.76 3.20 |
Daily Volume: | 2,714,959 |
Market Cap: | US$2.270B |
August 05, 2025 May 12, 2025 February 27, 2025 October 30, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load